GlassScriptPhysician profile
Cynthia Rizk
NPI 1043577414
$1,071.28
in general payments reported to CMS, 2019-2025
15 companies · $171 in 2025
The $171 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $38.48 · 2021: $22.61 · 2022: $291 · 2023: $144 · 2024: $271 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $216.26 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $177.94 | 2020-2024 | |
| Abbvie INC. | $131.23 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $114.63 | 2022-2023 | Lokelma |
| E.R. Squibb & Sons, L.L.C. | $91.76 | 2022-2023 | Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.61 | 2024-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $56.38 | 2022-2023 | Ultomiris |
| Pfizer INC. | $48.74 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.77 | 2025 | |
| Electromed, INC. | $22.61 | 2021 | |
| Boston Scientific Corporation | $21.95 | 2025 | Watchman Flx |
| Amgen INC. | $21.31 | 2019 | |
| Aimmune Therapeutics, INC. | $20.90 | 2024 | |
| Merck Sharp & Dohme LLC | $20.32 | 2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $17.87 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Rizk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.